JP2000506847A - ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法 - Google Patents

４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法

Info

Publication number
JP2000506847A
JP2000506847A JP9531444A JP53144497A JP2000506847A JP 2000506847 A JP2000506847 A JP 2000506847A JP 9531444 A JP9531444 A JP 9531444A JP 53144497 A JP53144497 A JP 53144497A JP 2000506847 A JP2000506847 A JP 2000506847A
Authority
JP
Japan
Prior art keywords
group
amino
piperidinyl
alkyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9531444A
Other languages
English (en)
Japanese (ja)
Inventor
フランク ヒンメルスバッハ
ゲオルク ダーマン
リューデン トーマス フォン
トーマス メッツ
Original Assignee
ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996108631 external-priority patent/DE19608631A1/de
Application filed by ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2000506847A publication Critical patent/JP2000506847A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
JP9531444A 1996-03-06 1997-03-03 ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法 Pending JP2000506847A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1996108631 DE19608631A1 (de) 1996-03-06 1996-03-06 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608631.0 1996-07-23
DE19629652A DE19629652A1 (de) 1996-03-06 1996-07-23 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652.8 1996-07-23
PCT/EP1997/001057 WO1997032881A1 (de) 1996-03-06 1997-03-03 4-amino-pyrimidin-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
JP2000506847A true JP2000506847A (ja) 2000-06-06

Family

ID=26023531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9531444A Pending JP2000506847A (ja) 1996-03-06 1997-03-03 ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法

Country Status (19)

Country Link
EP (1) EP0885226A1 (de)
JP (1) JP2000506847A (de)
KR (1) KR19990087550A (de)
CN (1) CN1212695A (de)
AU (1) AU710274B2 (de)
BG (1) BG102708A (de)
BR (1) BR9708312A (de)
CA (1) CA2243994A1 (de)
CZ (1) CZ281798A3 (de)
DE (1) DE19629652A1 (de)
EE (1) EE9800277A (de)
HU (1) HUP9901820A3 (de)
IL (1) IL125404A0 (de)
NO (1) NO984084D0 (de)
NZ (1) NZ331546A (de)
PL (1) PL328771A1 (de)
SK (1) SK120598A3 (de)
TR (1) TR199801749T2 (de)
WO (1) WO1997032881A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530212A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
JP2012510481A (ja) * 2008-12-01 2012-05-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1396489A1 (de) * 1999-01-27 2004-03-10 Pfizer Products Inc. Heteroaromatische Bicyclen als anti-Krebs Mittel
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
UA82517C2 (uk) * 2003-06-24 2008-04-25 Ньюросерч А/С Нові похідні 8-аза-біцикло[3.2.1]октану та їх застосування як інгібіторів ресорбції моноамінових медіаторів
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US20120316187A1 (en) 2009-11-13 2012-12-13 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (de) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (de) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP6297490B2 (ja) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド 診断マーカー
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP2976085A1 (de) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von chronischen lebererkrankungen im zusammenhang mit einer niedrigen hepcidinexpression
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
MX2017008421A (es) 2014-12-24 2018-03-23 Genentech Inc Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
RS62456B1 (sr) 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3788038B1 (de) 2018-05-04 2023-10-11 Amgen Inc. Kras-g12c-inhibitoren und verfahren zu deren verwendung
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3802537A1 (de) 2018-06-11 2021-04-14 Amgen Inc. Kras-g12c-inhibitoren zur behandlung von krebs
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
MA54547A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
ES2953821T3 (es) 2018-12-20 2023-11-16 Amgen Inc Inhibidores de KIF18A
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
EP3972973A1 (de) 2019-05-21 2022-03-30 Amgen Inc. Festkörperformen
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CA3159559A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4054719A1 (de) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras-inhibitoren
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
BR112022010086A2 (pt) 2020-01-07 2022-09-06 Revolution Medicines Inc Dosagem do inibidor de shp2 e métodos de tratamento de câncer
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4431867A1 (de) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530212A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
JP2012510481A (ja) * 2008-12-01 2012-05-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン

Also Published As

Publication number Publication date
DE19629652A1 (de) 1998-01-29
PL328771A1 (en) 1999-02-15
IL125404A0 (en) 1999-03-12
CN1212695A (zh) 1999-03-31
NZ331546A (en) 2000-03-27
EP0885226A1 (de) 1998-12-23
AU710274B2 (en) 1999-09-16
NO984084L (no) 1998-09-04
BG102708A (en) 1999-09-30
SK120598A3 (en) 1999-06-11
KR19990087550A (ko) 1999-12-27
HUP9901820A3 (en) 2001-10-29
NO984084D0 (no) 1998-09-04
EE9800277A (et) 1999-02-15
BR9708312A (pt) 1999-08-03
CA2243994A1 (en) 1997-09-12
TR199801749T2 (xx) 1998-12-21
WO1997032881A1 (de) 1997-09-12
HUP9901820A2 (hu) 1999-09-28
CZ281798A3 (cs) 1999-02-17
AU1925197A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
JP2000506847A (ja) ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法
EP2661435B1 (de) 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
AU730376B2 (en) Pyrimido{5,4-d}pyrimidines, medicaments containing these compounds, their use and process for their production
TWI557123B (zh) 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
CN1066149C (zh) 用作磷酸二酯酶iv抑制剂的二氮杂䓬并吲哚
KR20190016976A (ko) Pi3k 베타 저해제로서의 아자벤즈이미다졸 유도체
EA005098B1 (ru) Бициклические гетероциклы и фармацевтические композиции, содержащие эти соединения
EA005679B1 (ru) Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
DE10042059A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2000506153A (ja) ピリミド［５，４―ｄ］ピリミジン、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
EP0698025B1 (de) Ampa antagonisten und behandlungsmethode
BG63874B1 (bg) Производни на индол-2,3-дион-3-оксим
JPH03200786A (ja) ラクタム誘導体
KR20180061258A (ko) PI3Kβ 저해제로서의 퀴녹살린 및 피리도피라진 유도체
WO2019120194A1 (zh) 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
WO2019134573A1 (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
JP2004507537A (ja) キナゾリン化合物、この化合物を含有する医薬組成物、その使用及びその調製方法
CN114504574B (zh) 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物药物制剂及其制备方法
TW202313606A (zh) 取代的苯基－１ｈ－吡咯并［２，３－ｃ］吡啶衍生物
KR20190016954A (ko) Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체
WO2010122340A2 (en) Process 738
CN114634453B (zh) 喹唑啉衍生物制备方法及其应用
DE19608631A1 (de) 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MXPA98006850A (en) Derivatives 4-amino-pyrimidine, medications containing these compounds, their use and process for suproducc
WO2022112951A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate